This topic contains a solution. Click here to go to the answer

Author Question: What is the purpose of administering filgrastim (Neupogen) to a patient who is post-bowel resection ... (Read 43 times)

SAVANNAHHOOPER23

  • Hero Member
  • *****
  • Posts: 542
What is the purpose of administering filgrastim (Neupogen) to a patient who is post-bowel resection resulting from cancer?
 
  a. Decrease the gastrointestinal (GI) toxicity resulting from chemotherapeutic agents
  b. Suppress the immune response
  c. Work as an antiemetic and stimulate his appetite
  d. Increase the white blood cell (WBC) counts

Question 2

Which symptom is the patient who is receiving bleomycin (Blenoxane) therapy most likely to exhibit?
 
  a. Increased respiratory rate and cough
  b. Weight gain and peripheral edema
  c. Numbness and tingling of hands and feet
  d. Lethargy and orthostatic hypotension



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

CharlieArnold

  • Sr. Member
  • ****
  • Posts: 319
Answer to Question 1

ANS: D
Filgrastim works to stimulate WBC production and decrease the incidence of infection. Filgrastim is a colony stimulating factor, which stimulates WBC proliferation and maturation. It is particularly helpful for patients prone to neutropenia resulting from cancer therapy. Filgrastim does not affect GI toxicity, suppress immune response (it works to enhance it), or affect appetite or nausea.

Answer to Question 2

ANS: A
Compromised respiratory function may occur in patients receiving bleomycin therapy. Increased respiratory rate and cough can be signs that further problems are developing, such as heart failure. Bleomycin does not cause weight gain, peripheral edema, numbness and tingling of hands and feet, lethargy, or orthostatic hypotension.




SAVANNAHHOOPER23

  • Member
  • Posts: 542
Reply 2 on: Jul 24, 2018
Wow, this really help


deja

  • Member
  • Posts: 332
Reply 3 on: Yesterday
Gracias!

 

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

Did you know?

The toxic levels for lithium carbonate are close to the therapeutic levels. Signs of toxicity include fine hand tremor, polyuria, mild thirst, nausea, general discomfort, diarrhea, vomiting, drowsiness, muscular weakness, lack of coordination, ataxia, giddiness, tinnitus, and blurred vision.

Did you know?

Despite claims by manufacturers, the supplement known as Ginkgo biloba was shown in a study of more than 3,000 participants to be ineffective in reducing development of dementia and Alzheimer’s disease in older people.

Did you know?

Patients who cannot swallow may receive nutrition via a parenteral route—usually, a catheter is inserted through the chest into a large vein going into the heart.

Did you know?

Alzheimer's disease affects only about 10% of people older than 65 years of age. Most forms of decreased mental function and dementia are caused by disuse (letting the mind get lazy).

For a complete list of videos, visit our video library